APAC Schizophrenia Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Route, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$1.73 BnPlaceholder estimate
Estimate 2025$1.84 Bn20.8% of the global market
Projected 2034$3.08 Bn 67.5%Adds $1.24 Bn over 9 forecast years
CAGR 2025–20345.9%Faster than 13% of 180 Pharmaceuticals markets here
Key players5
APAC is 20.83% of the global market.
Among regions, the largest is North America at $4.03 Bn.
Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Teva Pharmaceutical, AbbVie Inc. (see all)
Active clinical trials
92 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Schizophrenia Drugs Market Analysis Executive Summary
Schizophrenia drugs control symptoms such as hallucinations and delusions, including long-acting injectables and new non-dopamine medicines.
Key segments of the schizophrenia Drugs market include drug class (Second-Generation Antipsychotics, Long-Acting Injectables and Muscarinic Agonists) and route (Oral and Injectable).
Asia Pacific Schizophrenia Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Schizophrenia Drugs Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the schizophrenia Drugs market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the schizophrenia Drugs market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the schizophrenia Drugs market.
Competitive Landscape for Schizophrenia Drugs Market in APAC
The schizophrenia Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Schizophrenia Drugs Market in APAC
Schizophrenia Drugs in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 92 studies on Schizophrenia Drugs that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for schizophrenia Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug Class
4.2 By Route
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Johnson & Johnson (Janssen)
7.2 Otsuka Pharmaceutical
7.3 Bristol Myers Squibb
7.4 Teva Pharmaceutical
7.5 AbbVie
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The schizophrenia Drugs market can be segmented based on various criteria, including drug class, route and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Schizophrenia Drugs right now, from free public sources.
Clinical trials
92 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Schizophrenia Drugs market in Asia Pacific?
Placeholder estimate: about $1.84 Bn in 2025, rising to about $3.08 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Schizophrenia Drugs market in Asia Pacific growing?
Placeholder estimate: about 5.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Schizophrenia Drugs market report cover?
The report splits the market by drug class (Second-Generation Antipsychotics, Long-Acting Injectables, Muscarinic Agonists, First-Generation Antipsychotics), route (Oral, Injectable) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Schizophrenia Drugs market?
Key players include Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Teva Pharmaceutical and AbbVie Inc..
What is driving the Schizophrenia Drugs market?
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the schizophrenia Drugs market. Governments and employers are investing more in mental health care.
How many clinical trials on Schizophrenia Drugs are running in Asia Pacific?
92 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Schizophrenia Drugs?
PubMed lists 16,702 papers on Schizophrenia Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
Canada
China
Japan
Germany
Brazil
Italy
France
UK
Ecuador
Spain
India
Saudi Arabia
Mexico
New Zealand
Australia
Russia
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Singapore
Thailand
Kenya
Aurobindo Pharma
Hikma Pharmaceuticals PLC